ArticleFrontiers in public health2025
Global trajectory and spatiotemporal epidemiological landscape of multidrug-resistant tuberculosis of spanning 46 years (1990-2035): implications for achieving global end TB goals.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Drug-resistant tuberculosis in conflict zones: a neglected global emergency.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although MDR-TB is recognized as a significant threat, systematic descriptions of its long-term (>30 years) global spatiotemporal evolution patterns are still limited. Objectives: This study conducted a 46-year spatiotemporal analysis of global MDR-TB (1990-2035) to provide key evidence for evaluating and refining the WHO End TB Strategy. Methods: We used Global Burden of Disease data to identify identified temporal inflection points in ASIR, ASDR, and DALYs using Joinpoint regression. Spatial clustering was quantified using Moran's I and Getis-Ord hotspot analysis. A Bayesian age-period-cohort model projected MDR-TB incidence from 2022 to 2035. Results: The male-to-female ratio was approximately 1.5:1. Incidence was highest at 30-60 years, deaths at 60+, DALYs peak at 45-60; children under 14 years of age significantly affected. ASIR rose from 0.97/100 k (1990) to 6.39/100 k (2000), then declined (APC: -3.15%) post-2005 to 5.62/100 k (2021); males exhibited a sharper increase (+2.39%) and slower decline (-0.71%). ASDR peaked at 2.12/100 k (2002; males 27% higher). DALYs peaked at 89.05/100 k (2003). Sub-Saharan Africa is hyperendemic (Moran's I = 12.38, Conclusion: MDR-TB has proven more challenging than anticipated, with persistent hotspots in sub-Saharan Africa and a disproportionate impact on males, the older adults, and children. Despite a marginal decline in ASIR to 5.46 per 100,000, the absolute number of cases is projected to rise to 480,000 by 2035 due to sustained population growth and aging. This will seriously hinder the WHO End TB Strategy. Addressing MDR-TB should prioritize key populations and regions, targeted resources, tailored interventions, sustained investment in diagnostics and treatment, and stronger government support for patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.